316 related articles for article (PubMed ID: 28523942)
1. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
2. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
3. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
4. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
Zhao J; Feng SS
Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
7. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Subhan MA; Torchilin VP
Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
9. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
12. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
Huang R; Yao X; Chen Y; Sun X; Lin Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
14. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
[TBL] [Abstract][Full Text] [Related]
15. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.
Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z
Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321
[TBL] [Abstract][Full Text] [Related]
16. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA.
Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659
[TBL] [Abstract][Full Text] [Related]
18. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
[TBL] [Abstract][Full Text] [Related]
19. RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.
Das M; Musetti S; Huang L
Nucleic Acid Ther; 2019 Apr; 29(2):61-66. PubMed ID: 30562145
[TBL] [Abstract][Full Text] [Related]
20. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
